Uliledlimab - CAS 2378407-27-1

Uliledlimab is a humanized monoclonal antibody with potent inhibitory activity against CD73, the ecto-5'-nucleotidase enzyme that catalyzes the conversion of extracellular AMP to adenosine. Uliledlimab reduces extracellular adenosine production, thereby modulating immunosuppressive pathways. Uliledlimab holds significant potential for use in immuno-oncology and cancer research.

CD73, cAMP

GPCR/G Protein, Immunology/Inflammation

2378379

0.955

-20°C

Ice Packs

Inhibitory Antibodies